Lv3
284 积分 2024-07-21 加入
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
3天前
已完结
Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
8天前
已完结
Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial
11天前
已完结
乳腺癌新辅助治疗的疗效预测和疗效评价专家共识（2025版）
19天前
已完结
Cancer-related Fatigue in Breast Cancer Survivors: A Review
1个月前
已完结
A Patent Review on FDA‐Approved Antibody‐Drug Conjugates, Their Linkers and Drug Payloads
1个月前
已完结
Human Epidermal Growth Factor Receptor 2-Mutant Non-Small-Cell Lung Cancer: Continued Progress But Challenges Remain
1个月前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
1个月前
已完结
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial
1个月前
已完结
皖公网安备34019202002308
